BackgroundCheck.run
Search For

Stanley James Hollenbach, 669121 Sanctuary Ct, Raleigh, NC 27617

Known as:
Stanley J Hollenbach Stanley J Hollenback Stanley Hollenbeck
Related to:
Kwang O Sanjuan 70 Clarita Sandiego 61 Juan N San Norman L Sanjuan 42 Norman S Juan 71

Stanley Hollenbach Phones & Addresses

9121 Sanctuary Ct, Raleigh, NC 27617   

450 Alta Vista Dr, South San Francisco, CA 94080    650-8718313   

San Mateo, CA   

San Francisco, CA   

450 Alta Vista Dr, South San Francisco, CA 94080    415-8718313   

Social networks

Stanley James Hollenbach

Linkedin

Work

Company: Novan, inc. Mar 2017 Position: Senior vice president of research and development

Education

School / High School: University of North Carolina at Charlotte 1976 to 1981

Skills

Biotechnology • Pharmaceutical Industry • Drug Discovery • Clinical Development • Drug Development • Life Sciences • Biopharmaceuticals • Cro • Fda • Lifesciences • Clinical Trials • Technology Transfer • Oncology

Industries

Biotechnology
Get Report
Control this profile

Mentions for Stanley James Hollenbach

Stanley Hollenbach resumes & CV records

Resumes

Stanley Hollenbach Photo 9

Senior Vice President Of Research And Development

Location:
9121 Sanctuary Ct, Raleigh, NC 27617
Industry:
Biotechnology
Work:
Novan, Inc.
Senior Vice President of Research and Development Portola Pharmaceuticals Jan 2004 - Mar 2014
Vice President of Pharmacology Novan, Inc. Jan 2004 - Mar 2014
Vice President, Research and Nonclinical Development
Education:
University of North Carolina at Charlotte 1976 - 1981
Skills:
Biotechnology, Pharmaceutical Industry, Drug Discovery, Clinical Development, Drug Development, Life Sciences, Biopharmaceuticals, Cro, Fda, Lifesciences, Clinical Trials, Technology Transfer, Oncology

Publications & IP owners

Us Patents

Combination Anticoagulant Therapy With A Compound That Acts As A Factor Xa Inhibitor

US Patent:
8455440, Jun 4, 2013
Filed:
Aug 19, 2011
Appl. No.:
13/213912
Inventors:
Uma Sinha - San Francisco CA, US
Stanley J. Hollenbach - South San Francisco CA, US
Patrick Andre - San Mateo CA, US
Assignee:
Millennium Pharmaceuticals, Inc. - Cambridge MA
International Classification:
A61K 38/57
US Classification:
514 144, 514 137, 514 149, 514183, 514185, 514188, 424 9464
Abstract:
The present invention is directed to methods of using combination therapies containing [2-({4-[(dimethylamino)iminomethyl]phenyl}carbonylamino)-5-methoxyphenyl]-N-(5-chloro(2-pyridyl))carboxamide for the treatment of thrombotic disease(s) and pharmaceutical compositions thereof.

Unit Dose Formulations And Methods Of Treating Thrombosis With An Oral Factor Xa Inhibitor

US Patent:
2008015, Jun 26, 2008
Filed:
Dec 7, 2007
Appl. No.:
11/999957
Inventors:
Uma Sinha - San Francisco CA, US
Stanley J. Hollenbach - South San Francisco CA, US
Keith Abe - South San Francisco CA, US
International Classification:
A61K 31/44
A61K 31/4439
A61K 31/4545
G01N 33/15
A61P 7/02
US Classification:
514318, 514352, 514341, 514343, 436 69
Abstract:
Unit doses of factor Xa inhibitor compounds and methods of using these compounds for inhibiting blood coagulation in a human patient are taught herein. The unit dose of the factor Xa inhibitor compounds disclosed herein required to inhibit coagulation in a primate is lower than the unit dose required to obtain similar levels of coagulation inhibition in other animal models, such as rodents. Also taught are in vitro assays useful in predicting in vivo antithrombotic activity in humans.

Combination Anticoagulant Therapy With A Compound That Acts As A Factor Xa Inhibitor

US Patent:
2008025, Oct 16, 2008
Filed:
Apr 11, 2008
Appl. No.:
12/101644
Inventors:
Uma Sinha - San Francisco CA, US
Stanley J. Hollenbach - South San Francisco CA, US
Patrick Andre - San Mateo CA, US
International Classification:
A61K 39/395
A61K 31/44
A61K 38/12
A61K 31/445
A61K 31/4365
A61K 31/519
A61K 31/47
A61K 31/727
A61K 31/60
A61P 7/02
US Classification:
4241411, 514352, 514 10, 514331, 514301, 5142621, 514312, 514 56, 514165
Abstract:
The present invention is directed to methods of using combination therapies containing [2-({4-[(dimethylamino)iminomethyl]phenyl}carbonylamino)-5-methoxyphenyl]-N-(5-chloro(2-pyridyl))carboxamide for the treatment of thrombotic disease(s) and pharmaceutical compositions thereof.

Unit Dose Formulation Of Antidotes For Factor Xa Inhibitors And Methods Of Using The Same

US Patent:
2011001, Jan 20, 2011
Filed:
Jul 14, 2010
Appl. No.:
12/836536
Inventors:
UMA SINHA - SAN FRANCISCO CA, US
GENMIN LU - BURLINGAME CA, US
ATHIWAT HUTCHALEELAHA - REDWOOD CITY CA, US
STANLEY J. HOLLENBACH - SOUTH SAN FRANCISCO CA, US
International Classification:
A61K 38/16
A61P 7/04
US Classification:
514 137, 514 212
Abstract:
The present invention relates unit dose formulations of antidotes to anticoagulants targeting factor Xa. Disclosed herein are methods of stopping or preventing bleeding in a patient that is currently undergoing anticoagulant therapy with a factor Xa inhibitor.

Combination Anticoagulant Therapy With A Compound That Acts As A Factor Xa Inhibitor

US Patent:
2013031, Nov 28, 2013
Filed:
May 8, 2013
Appl. No.:
13/889982
Inventors:
Stanley J. Hollenbach - South San Francisco CA, US
Patrick Andre - San Mateo CA, US
Assignee:
Millennium Pharmaceuticals, Inc. - Cambridge MA
International Classification:
A61K 31/44
A61K 45/06
A61K 31/4465
A61K 39/395
A61K 38/12
US Classification:
4241331, 514352, 514 149, 514331
Abstract:
The present invention is directed to methods of using combination therapies containing [2-({4-[(dimethylamino)iminomethyl]phenyl}carbonylamino)-5-methoxyphenyl]-N-(5-chloro(2-pyridyl))carboxamide for the treatment of thrombotic disease(s) and pharmaceutical compositions thereof.

Unit Dose Formulation Of Antidotes For Factor Xa Inhibitors And Methods Of Using The Same

US Patent:
2023000, Jan 5, 2023
Filed:
Jan 5, 2022
Appl. No.:
17/569402
Inventors:
- Boston MA, US
Genmin Lu - Burlingame CA, US
Athiwat Hutchaleelaha - Redwood City CA, US
Stanley J. Hollenbach - South San Francisco CA, US
International Classification:
A61K 38/48
C12N 9/64
A61K 9/00
Abstract:
The present invention relates unit dose formulations of antidotes to anticoagulants targeting factor Xa. Disclosed herein are methods of stopping or preventing bleeding in a patient that is currently undergoing anticoagulant therapy with a factor Xa inhibitor.

Unit Dose Formulation Of Antidotes For Factor Xa Inhibitors And Methods Of Using The Same

US Patent:
2021008, Mar 25, 2021
Filed:
Jul 30, 2020
Appl. No.:
16/943933
Inventors:
- South San Francisco CA, US
Genmin Lu - Burlingame CA, US
Athiwat Hutchaleelaha - Redwood City CA, US
Stanley J. Hollenbach - South San Francisco CA, US
International Classification:
A61K 38/48
C12N 9/64
A61K 9/00
Abstract:
The present invention relates unit dose formulations of antidotes to anticoagulants targeting factor Xa. Disclosed herein are methods of stopping or preventing bleeding in a patient that is currently undergoing anticoagulant therapy with a factor Xa inhibitor.

Compositions For Treating Inflammation And Methods Of Treating The Same

US Patent:
2019001, Jan 17, 2019
Filed:
Mar 2, 2017
Appl. No.:
16/081708
Inventors:
- Morrisville NC, US
Ryan Doxey - Raleigh NC, US
Kimberly McHale - Hillsborough NC, US
Stanley J. Hollenbach - Raleigh NC, US
International Classification:
A61K 31/132
A61K 33/00
A61K 9/00
A61P 29/00
A61K 9/06
A61P 17/02
A61P 27/16
A61P 17/06
A61P 17/00
Abstract:
Provided herein are compositions useful for treating inflammation in a subject and methods of decreasing inflammation in the skin, mucosa, and/or eye of a subject comprising applying a pharmaceutical composition that includes an NO-releasing compound to the skin, mucosa, and/or eye of the subject in an amount sufficient to decrease inflammation.

Possible Relatives

Elaine R Hollenbach  Harry C Hollenbach  Jayme A Hollenbach  Jeffrey A Hollenbach  Jessica R Hollenbach  Jil A Hollenbach  Margaret Hollenbach  Stanley S Johnson  Stanley L Stancil  Stanley B Johnston 

NOTICE: You may not use BackgroundCheck or the information it provides to make decisions about employment, credit, housing or any other purpose that would require Fair Credit Reporting Act (FCRA) compliance. BackgroundCheck is not a Consumer Reporting Agency (CRA) as defined by the FCRA and does not provide consumer reports.